APO-CLOMIPRAMINE 25 MG
CLOMIPRAMINE HYDROCHLORIDE : 25 MG · DIN 02040778 · APOTEX INC
Health Canada status: APPROVED
What is APO-CLOMIPRAMINE?
APO-CLOMIPRAMINE 25 MG contains CLOMIPRAMINE HYDROCHLORIDE : 25 MG. It is listed in the Health Canada Drug Product Database under DIN 02040778, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as approved, status dated 05-Nov-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is APO-CLOMIPRAMINE used for?
Treatment of depression (including associated anxiety) and treatment of obsessions and compulsions in patients with obsessive compulsive disorder (OCD).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02040778 |
|---|---|
| Brand name | APO-CLOMIPRAMINE |
| Generic / active ingredient | CLOMIPRAMINE HYDROCHLORIDE : 25 MG |
| Manufacturer | APOTEX INC |
| Strength | 25 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N06AA04 CLOMIPRAMINE |
| AHFS class | 28:16.04.28 |
| Biosimilar | No |
| Health Canada status | APPROVED |
| Status date | 05-Nov-2018 |
How is it administered?
Individualize dose. Depression: Start 25 mg/day, increase to 150-200 mg/day. OCD: Start 25 mg/day, increase to 100-250 mg/day. Administer with meals initially; can be single bedtime dose for maintenance.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (Section 11 referenced but text cuts off).
How is it supplied?
Not explicitly detailed in provided text (mentions 10 mg, 25 mg, 50 mg strengths).
Contraindications
Hypersensitivity to clomipramine or TCAs; MAOI use within 14 days; acute recovery phase of myocardial infarction; acute congestive heart failure; liver/kidney damage; history of blood dyscrasias; glaucoma.
Warnings and precautions
Serious risk of cardiovascular effects (arrhythmias, tachycardia); anticholinergic effects; lowers seizure threshold; clinical worsening and suicide risk; serotonin syndrome risk.
What can be used instead?
Other Canadian products sharing ATC code N06AA04 CLOMIPRAMINE. 5 of 35 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ANAFRANIL | 10 MG | TABLET | APOTEX INC | MARKETED | DIN 00330566 |
| ANAFRANIL | 25 MG | TABLET | APOTEX INC | MARKETED | DIN 00324019 |
| ANAFRANIL | 50 MG | TABLET | APOTEX INC | MARKETED | DIN 00402591 |
| TARO-CLOMIPRAMINE | 25 MG | CAPSULE | TARO PHARMACEUTICALS INC | MARKETED | DIN 02497506 |
| TARO-CLOMIPRAMINE | 50 MG | CAPSULE | TARO PHARMACEUTICALS INC | MARKETED | DIN 02497514 |
| ACT CLOMIPRAMINE | 10 MG | TABLET | ACTAVIS PHARMA COMPANY | CANCELLED POST MARKET | DIN 02244816 |
| ACT CLOMIPRAMINE | 25 MG | TABLET | ACTAVIS PHARMA COMPANY | CANCELLED POST MARKET | DIN 02244817 |
| ACT CLOMIPRAMINE | 50 MG | TABLET | ACTAVIS PHARMA COMPANY | CANCELLED POST MARKET | DIN 02244818 |
| ALTIUS-CLOMIPRAMINE | 10 MG | TABLET | ASPRI PHARMA CANADA INC | CANCELLED PRE MARKET | DIN 02446758 |
| ALTIUS-CLOMIPRAMINE | 25 MG | TABLET | ASPRI PHARMA CANADA INC | CANCELLED PRE MARKET | DIN 02446766 |
Who else supplies CLOMIPRAMINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CLOMIPRAMINE appears in 47 registered pack listings across 10 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.